Paul Herzich, the Chief Technology Officer at Solid Biosciences Inc. (NASDAQ:SLDB), reported the sale of 3,616 shares of the company's common stock on February 18, 2026, according to a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction produced total gross proceeds of $21,057, based on a weighted average sale price of $5.8233 per share. Individual trade prices recorded in the filing ranged from $5.23 to $6.14.
The filing indicates the disposition was executed to satisfy withholding tax obligations that arose when previously granted restricted stock units vested. Earlier in the same month, on February 13, 2026, Herzich exercised restricted stock units and thereby acquired 7,187 shares of Solid Biosciences common stock.
Company pipeline and regulatory developments
Solid Biosciences also disclosed several program milestones that are likely to be of interest to investors tracking the company's pipeline. The firm reached alignment with the U.S. Food and Drug Administration on the design of its Phase 3 IMPACT DUCHENNE clinical trial for its Duchenne muscular dystrophy candidate, SGT-003. The agreed-upon design calls for a randomized, double-blind, placebo-controlled study.
Separately, Solid Biosciences reported dosing 33 participants in its Phase 1/2 INSPIRE DUCHENNE clinical trial. The company stated that the SGT-003 therapy has been generally well tolerated across those participants, with no major adverse effects observed in the data announced.
On another front, Solid Biosciences received Orphan Drug designation from the FDA for its investigational gene therapy SGT-212, which targets Friedreich's ataxia. The company has also dosed the first participant in the Phase 1b FALCON trial for SGT-212.
Analyst view
Following the company's regulatory and clinical updates, Citizens reiterated a Market Outperform rating on Solid Biosciences with a $15.00 price target. The firm cited the company's recent progress in regulatory alignment and advancement of clinical studies in maintaining its positive view.
Taken together, the corporate disclosures include both an insider stock transaction tied to RSU activity and multiple program-level developments spanning both Duchenne muscular dystrophy and Friedreich's ataxia programs. The insider sale was described in regulatory filings as a tax-related disposition following the vesting and exercise of equity awards.